Fulcrum Therapeutics stock plunges on FDA concerns
Analysis based on 9 articles · First reported Jun 02, 2026 · Last updated Jun 04, 2026
The stock of Fulcrum Therapeutics plunged 50% following the disclosure of FDA safety concerns and the discontinuation of its lead drug candidate, pociredir. This event has led to a securities fraud investigation by Levi & Korsinsky, impacting investor confidence in Fulcrum Therapeutics and potentially other biotechnology companies developing similar drug classes.
Fulcrum Therapeutics, a publicly traded company, experienced a 50% stock plunge on June 1, 2026, after disclosing United States — Food and Drug Administration safety concerns related to the PRC2 inhibitor drug class, specifically regarding potential malignancy risk. This led to the immediate discontinuation of its lead candidate, pociredir, and the initiation of a strategic review. The law firm Levi & Korsinsky has launched an investigation into Fulcrum Therapeutics for potential securities fraud, examining whether CEO Alex Sapir and the company made materially false or misleading statements to investors regarding pociredir's safety profile and regulatory outlook prior to the disclosure. The investigation also considers the impact of existing long-term financial commitments, such as a $25.1 million facility lease and a licensing agreement with CAMP4 Therapeutics, which remain in place despite the program's termination.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard